Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Harith Rajagopalan
|
| gptkbp:clinicalTrialPhase |
Revita-2
Revita-T2Di |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
metabolic diseases
treatments for type 2 diabetes |
| gptkbp:foundedYear |
2010
|
| gptkbp:founder |
Harith Rajagopalan
Michael G. Martin |
| gptkbp:headquartersLocation |
gptkb:Lexington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fractyl Health
|
| gptkbp:industry |
gptkb:biotechnology
medical devices |
| gptkbp:IPODate |
2024
|
| gptkbp:mission |
to transform the treatment of metabolic diseases
|
| gptkbp:notableProduct |
Revita DMR System
|
| gptkbp:stockExchange |
gptkb:Nasdaq
|
| gptkbp:stockSymbol |
gptkb:GUTS
|
| gptkbp:website |
https://www.fractyl.com/
|
| gptkbp:bfsParent |
gptkb:Stanley_Lapidus
|
| gptkbp:bfsLayer |
7
|